Crossmark

Prognosis of metastatic bone cancer and myeloma patients and long-term risk of medication-related osteonecrosis of the jaw (MRONJ): some critical points

Crossref DOI link: https://doi.org/10.1007/s00520-022-07214-z

Published Online: 2022-07-27

Published Print: 2022-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Fusco, Vittorio https://orcid.org/0000-0003-0263-9820
Rossi, Maura

Fasciolo, Antonella

Gambino, Alessio

Palmeri, Serena
License Information

Text and Data Mining valid from 2022-07-27

Version of Record valid from 2022-07-27
More Information

Article History

Received: 22 March 2022

Accepted: 9 June 2022

First Online: 27 July 2022

Declarations

:

: Not applicable

: Not applicable

: Not applicable

: Vittorio Fusco received honoraria as a consultant by Merck; Maura Rossi received travel grants from AAA/Novartis; other authors declared no conflict of interest.

Document is current

Any future updates will be listed below